ArticleBritish journal of cancer2014
Cdc20 and securin overexpression predict short-term breast cancer survival.
Article in British journal of cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
104 citing papers in PubMed, 2 syntheses or guidelines pooled it, 170 citations in OpenAlex.
- Prognostic significance of CDC20 expression in malignancy patients: A meta-analysis.Frontiers in oncology · 2022Pooled it
- CDC20 overexpression leads to poor prognosis in solid tumors: A system review and meta-analysis.Medicine · 2018Pooled it
- Molecular Mechanisms and Molecular Subtype-Specific Responses to Paclitaxel in Breast Cancer Cells.Molecules (Basel, Switzerland) · 2026Article
- Molecular insights for the tumor suppressor role of SPOP in prostate cancer.Biochimica et biophysica acta. Reviews on cancer · 2026Review
- Inhibition of CDC20 suppresses the development and progression of mantle cell lymphoma through PI3K/AKT pathway.Annals of hematology · 2026Article
- CDC20 Regulates the Progression of Clear Cell Renal Cell Carcinoma via the Wnt/β-Catenin Signaling Pathway.Genetics research · 2026Article
- A signature of correlated CDC20 and UBCH10 expression indicates poor prognosis in primary head and neck squamous cell carcinoma.BMC cancer · 2025Article
- Astragalus polysaccharide regulates the cervical cancer cell cycle and inhibits cisplatin resistance by blocking the Wnt/β-catenin pathway through the PPARD/CDC20 axis.Cytotechnology · 2025Article
- Significant prognostic value of cell-cycle proteins in early-stage small cell carcinoma of cervix.Scientific reports · 2025Article
- Elevated KNSTRN as a potential indicator for triple-negative breast cancer progression and immune infiltration.Frontiers in immunology · 2025Article
- Emerging Roles of PTTG1/Securin in Breast Cancer.Journal of Cancer · 2025Review
- Network-based insights into miR-30a-5p-mediated regulation and EGCG targeting in triple-negative breast cancer.Frontiers in bioinformatics · 2025Article
- CDC20 and CCNB1 Overexpression as Prognostic Markers in Bladder Cancer.Diagnostics (Basel, Switzerland) · 2024Article
- Prognostic and Therapeutic Implications of Cell Division Cycle 20 Homolog in Breast Cancer.Cancers · 2024Article
- Antitumor Effect of Apcin on Endometrial Carcinoma via p21-Mediated Cell Cycle Arrest and Apoptosis.Current medical science · 2024Article
- HOXD8 suppresses renal cell carcinoma growth by upregulating SHMT1 expression.Cancer science · 2023Article
- Epigenetic reprogramming of cell cycle genes by ACK1 promotes breast cancer resistance to CDK4/6 inhibitor.Oncogene · 2023Article
- Structure-based virtual screening for identification of potential CDC20 inhibitors and their therapeutic evaluation in breast cancer.3 Biotech · 2023Article
- Differentially expressed discriminative genes and significant meta-hub genes based key genes identification for hepatocellular carcinoma using statistical machine learning.Scientific reports · 2023Article
- p53 directly downregulates the expression of CDC20 to exert anti-tumor activity in mantle cell lymphoma.Experimental hematology & oncology · 2023Article
44 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCdc20 is an essential component of cell division and responsible for anaphase initiation regulated by securin degradation. Cdc20 function is strongly regulated by the spindle assembly checkpoint to ensure the timely separation of sister chromatids and integrity of the genome. We present the first results on Cdc20 in a large clinical breast cancer material.
methodsThe study was based on 445 breast cancer patients with up to 20 years of follow-up (mean 10.0 years). DNA content was determined by image cytometry on cell imprints, and Cdc20 and securin immunohistochemistry on tissue microarrays of breast cancer tissue.
resultsIn our results, high Cdc20 and securin expression was associated with aneuploid DNA content. In prognostic analyses, high Cdc20 immunoexpression alone and in combination with high securin immunoexpression indicated aggressive course of disease and up to 6.8-fold (P<0.001) risk of breast cancer death. Particularly, high Cdc20 and securin immunoexpression identified a patient subgroup with extremely short, on average 2.4 years, breast cancer survival and triple-negative breast cancer (TNBC) subtype.
conclusionsWe report for the first time the association of high Cdc20 and securin immunoexpression with extremely poor outcome of breast cancer patients. Our experience indicates that Cdc20 and securin are promising candidates for clinical applications in breast cancer prognostication, especially in the challenging prognostic decisions of TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.